SPRY · ARS Pharmaceuticals
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $4.54
Note written ·
Price against the kill line
14.3% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $4.54, on record since 11 November 2026. The shares are down 37.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $4.54, which sits over the late-October closes and the 50-day average and would show the shares leading again. A commercial formulary addition announced by the company would point the same way.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 37.7
- Revenue, change on a year (%)
- +16.0
- Operating margin (%)
- −90.6
- Free cash flow, four quarters ($M)
- −183
- Net cash, cash less debt ($M)
- 16.5
- Enterprise value to sales (×)
- 3.1
- Free-cash-flow yield (%)
- −46.8
All filed numbers
What ARS Pharmaceuticals reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 37.7 | +16.0 | −90.6 |
| first filed | 33.7 | +114.2 | −182.6 |
| first filed | 22.7 | +184.5 | −265.2 |
| first filed | 28.1 | −67.6 | −147.6 |
| first filed | 32.5 | +1471.6 | −163.7 |
| first filed | 15.7 | +3043.4 | −302.9 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −200 | −35.6 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +0.9 |
| Operating cash flow ($M) | −183 |
| Capital spending ($M) | 0.0 |
| Free cash flow ($M) | −183 |
| Cash and short-term investments ($M) | 138 |
| Debt ($M) long-term debt | 122 |
| Net cash, cash less debt ($M) | 16.5 |
| Deferred revenue ($M) −13.2% on a year | 1.6 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 52.8 |
| Inventory ($M) | 33.4 |
| Shareholders' equity ($M) | −12.0 |
| Market value ($M) | 391 |
| Enterprise value, market value plus net debt ($M) | 375 |
| Enterprise value to sales (×) | 3.1 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | Not meaningful |
| Free-cash-flow yield (%) | −46.8 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 19.7% of shares outstanding sold short, 12.6 days of average trading to cover, −6.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $284K |
The thesis
ARS Pharmaceuticals sells one product, the needle-free epinephrine spray neffy, and the shares are more likely to lag the S&P 500 than lead it over the next three months. The third-quarter 2026 report grew sales but missed analyst estimates, and the company again announced no new commercial formulary additions (insurance coverage lists). The fourth-quarter 2026 report, whose date the company has not yet confirmed, shows whether revenue can keep rising without that coverage.
The shares closed at $3.81 on 12 November 2026, up from the closing low of $2.65 on 5 November 2026 but 71.0% below the intraday 52-week high of $13.15 on 12 January 2026 and 32.6% lower over three months (adjusted daily closes). The rebound has not been tied to any new company disclosure in company news or SEC filings.
U.S. neffy net product revenue was $33.4 million in the third quarter of 2026, against $26.2 million in the second quarter and $31.3 million in the third quarter of 2025 (company results, SEC Exhibit 99.1, 5 November 2026). Total revenue of $37.71 million missed the $41.992 million analyst estimate, and the loss of $0.36 per share missed the $0.31 estimate (Benzinga, 5 November 2026).
The price already reflects a sharp reset: at $3.81 the shares trade far below the $20 target of Cantor Fitzgerald and the $17 target of Raymond James, both set on 6 November 2026.
Bullish and bearish views on ARS Pharmaceuticals, Inc.
The bull case on ARS Pharmaceuticals, Inc. (SPRY), in brief: sequential revenue recovered. The bear case: results missed estimates.
Bull case
- Sequential revenue recovered. U.S. neffy net product revenue reached $33.4 million in the third quarter of 2026 from $26.2 million in the second quarter (company results, 5 November 2026). It also exceeds the $31.3 million of the third quarter of 2025.
- Targeted accounts are gaining share. Share of U.S. epinephrine prescriptions in field-targeted accounts was about 9% in the third quarter of 2026, up from 6% a year earlier. Overall share was 5% (company results, 5 November 2026).
- Prescriber base keeps widening. The company counted 19,605 unique prescribers in the third quarter of 2026, up 49% from a year earlier (company results, 5 November 2026).
- Losses are narrowing. Net loss was $35.6 million in the third quarter of 2026, against $62.3 million in the second quarter and $51.2 million in the third quarter of 2025. The company reaffirmed cash-flow breakeven by year-end 2027 (company results, 5 November 2026).
- Analysts keep positive ratings. On 6 November 2026 Cantor Fitzgerald kept Overweight and lowered its target to $20 from $30, and Raymond James moved to Outperform with a $17 target (Benzinga).
Bear case
- Results missed estimates. Total revenue of $37.71 million fell short of the $41.992 million estimate (Benzinga, 5 November 2026). Both analyst firms lowered their stance or target on 6 November 2026.
- Debt exceeds cash. At 30 September 2026 the company held $138.4 million of cash and short-term investments against $121.8 million of net term loans and a $75.2 million financing liability. Stockholders' deficit was $12.0 million (company results).
- Coverage has not arrived. The third-quarter release announced no formulary additions, and non-targeted accounts hold about 2% share (company results, 5 November 2026).
- Spending guidance changed form. The company guided second-half 2026 selling, general and administrative plus research and development expense to $114–126 million including stock-based compensation (company results, 5 November 2026). The earlier $100–110 million guide was a cash measure, so the two are not directly comparable.
- One product carries the revenue. A payer decision, safety headline or supply problem would hit the whole revenue line.
Price setup
The shares closed at $3.81 on 12 November 2026 after four sessions of gains from $2.65 on 5 November 2026: $2.79 on 6 November 2026, $3.15 on 9 November 2026, $3.57 on 10 November 2026 and $3.95 on 11 November 2026. The close of 12 November 2026 was lower than the day before.
The 50-day average is $4.11 and the 200-day average is $7.07 (adjusted closes, as of 12 November 2026), so the shares trade below both. The close of $5.65 on 14 August 2026 is the three-month reference. The shares were at $4.32 on 22 October 2026, so the rebound has recovered part of the post-report fall but not the late-October range.
The 52-week closing low of $2.65 on 5 November 2026 is the floor the rebound began from. A close back toward the 50-day average would put the shares in the area where they traded before the third-quarter report.
Catalysts ahead
- Unscheduled: Any commercial formulary addition or coverage decision for neffy. The July 2026 coverage cycle brought no additions and the third-quarter release again announced none; a decision would be the first evidence of repair.
- ~March 2027 (est.): Fourth-quarter 2026 results. Shows whether U.S. neffy net product revenue holds above the $33.4 million of the third quarter without new coverage, and whether the end-2027 breakeven target stands.
- Q1 2027 (est.): Interim Phase 2b data for ARS-2, the company's next epinephrine program. The only dated pipeline readout; it matters only if the company funds itself to reach it.
What would change the view
A daily close above $4.54, which sits over the late-October closes and the 50-day average and would show the shares leading again. A commercial formulary addition announced by the company would point the same way.
What it trades with
The shares trade on their own news: payer decisions, quarterly neffy revenue and financing. Small-cap biotech indexes set the background for risk appetite. ALK-Abelló, which sells neffy outside the U.S., supplies ex-U.S. revenue to ARS as supply sales, milestones and royalties, so its launches feed the reported revenue line.
The evidence, claim by claim (7)
- U.S. neffy net product revenue was $33.4 million in the third quarter of 2026, versus $26.2 million in the second quarter of 2026 and $31.3 million in the third quarter of 2025; total revenue was $37.7 million. ARS Pharmaceuticals third-quarter 2026 results, SEC Exhibit 99.1 (8-K) · as of
- Total revenue of $37.71 million missed the $41.992 million analyst estimate; loss per share of $0.36 missed the $0.31 estimate. Benzinga earnings summary · as of
- Net loss was $35.6 million in the third quarter of 2026, versus $62.3 million in the second quarter and $51.2 million in the third quarter of 2025. ARS Pharmaceuticals third-quarter 2026 results, SEC Exhibit 99.1 · as of
- Cash, equivalents and short-term investments were $138.4 million; term loans were $121.8 million (net), a financing liability $75.2 million, and stockholders' deficit $12.0 million. ARS Pharmaceuticals third-quarter 2026 results, SEC Exhibit 99.1 · as of
- U.S. epinephrine share was 5% overall and about 9% in field-targeted accounts (6% a year earlier); 19,605 unique prescribers, up 49% from a year earlier. ARS Pharmaceuticals third-quarter 2026 results, SEC Exhibit 99.1 · as of
- The company guided second-half 2026 selling, general and administrative plus research and development expense to $114–126 million including stock-based compensation, reaffirmed cash-flow breakeven by year-end 2027, and announced no new formulary additions. ARS Pharmaceuticals third-quarter 2026 results, SEC Exhibit 99.1 · as of
- Cantor Fitzgerald kept Overweight and lowered its price target to $20 from $30; Raymond James moved to Outperform with a $17 target. Benzinga analyst headlines · as of
Sources
- ARS Pharmaceuticals, Inc. - Form 8-K - FY2026 · sec.gov ·
- ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results · globenewswire.com ·
- ARS Pharmaceuticals Reports Q3 2026 Revenue of $37.7 Million and Net Loss of $(0.36) per Share, Below Analyst Estimates · gurufocus.com
- ARS Pharma (SPRY) Q3 2026 Earnings Call Transcript · fool.com ·